Loading the page…
Nasdaq 100
Moderna, Inc., Health Care
$221.72
−0.47% on the day
Close of Fri, Oct 30, 2026
| Quarter ending | Jun 2026 | Mar 2026 | Dec 2025* | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024* | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $145M | $389M | $678M | $1.0B | $142M | $108M | $966M | $1.9B |
| Gross margin | 35.9% | -145.5% | 33.3% | 79.6% | 16.2% | 16.7% | 23.5% | 72.4% |
| Operating margin | -562.1% |
Research
Figures from SEC filings and daily closes; results dates and headlines from Yahoo Finance and Nasdaq; insider trades from SEC Form 4. For learning, not investment advice.
| -356.8% |
| -126.4% |
| -25.6% |
| -638.7% |
| -972.2% |
| -129.0% |
| -3.8% |
| Net margin | -539.3% | -345.2% | -121.8% | -19.7% | -581.0% | -899.1% | -115.9% | 0.7% |
|---|
| EPS, diluted | −$1.97 | −$3.40 | −$2.10 | −$0.51 | −$2.13 | −$2.52 | −$2.91 | $0.03 |
|---|
From the company's SEC filings, newest first. * A fiscal fourth quarter: the year's 10-K less its first three quarters.
The same ranks the builder's sliders blend. Small and Wild are Big and Calm turned over.
| Measure | MRNA | Higher than |
|---|---|---|
| Earnings yield (earnings ÷ price) | -3.6% | 3% |
| Book yield (book value ÷ price) | 7.6% | 34% |
| Free cash flow yield | -2.3% | 3% |
| Buyback yield | 0.0% | 29% |
| Revenue growth, a year | -39.9% | 0% |
| EPS growth, a year | 21.8% | 58% |
| Return on equity | -46.6% | 2% |
| Return on assets | -28.7% | 2% |
| Net margin | -141.4% | 2% |
| Liabilities ÷ assets | 38.3% | 29% |
| Past year, skipping last month | 664.9% | 99% |
| Past 6 months, skipping last month | 316.4% | 100% |
| Volatility, a year's worth | 366.3% | 100% |
"Higher than" is the share of the 100 with a lower figure. Financial figures from SEC filings, market figures from daily closes. Dividend yield and beta are under Valuation below.
Modeled on each investor's published approach, not their real picks. Ask opens a chat with that bot about MRNA in Claude or ChatGPT. Connect your assistant →
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
From Yahoo Finance, modernatx.com
Beat the forecast in 3 of the last 4 quarters.
The stock's move is from the close before the report to the close after it.
Picked by YouTube search, not by us. Someone else's view, not advice.
Jobs, Midterm Elections, Apple, Palantir, McDonald’s, Moderna, and More to Watch This WeekBarrons.com, 4h ago
Merck stock rises as its cancer strategy gets personalTheStreet, 6h ago
How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataSimply Wall St., Oct 31Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
Every transaction, in AdvancedSEC Form 4, public domain. The latest 40 of 64 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Open-market buys and sells are the ones that say something; awards, exercises and tax withholding are routine.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Hoge StephenPresident | Option exercise | +76,452 | $12.21 | $933K | Form 4 ↗ |
| Oct 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −39,145 | $220.72 | $8.6M | Form 4 ↗ |
| Oct 14, 2026 | Hoge StephenPresident | Option exercise | +76,453 | $12.21 | $933K | Form 4 ↗ |
| Oct 14, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −39,224 | $213.48average | $8.4M | Form 4 ↗ |
| Oct 5, 2026 | Mock James MCFO | Units vested | +1,454 | — | — | Form 4 ↗ |
| Oct 5, 2026 | Mock James MCFO | Tax withholding | −704 | $190.01 | $134K | Form 4 ↗ |
| Sep 15, 2026 | Hoge StephenPresident | Option exercise | +76,452 | $12.21 | $933K | Form 4 ↗ |
| Sep 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −40,281 | $146.07 | $5.9M | Form 4 ↗ |
| Sep 14, 2026 | Hoge StephenPresident | Option exercise | +76,453 | $12.21 | $933K | Form 4 ↗ |
| Sep 14, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −40,294 | $144.13 | $5.8M | Form 4 ↗ |
| Sep 10, 2026 | Mock James MCFO | Option exercise | +19,836 | $30.96 | $614K | Form 4 ↗ |
| Sep 10, 2026 | Mock James MCFO | Sold on the market10b5-1 plan | −34,836 | $134.49 | $4.7M | Form 4 ↗ |
| Sep 4, 2026 | Mock James MCFO | Units vested | +11,797 | — | — | Form 4 ↗ |
| Sep 4, 2026 | Mock James MCFO | Tax withholding | −5,704 | $148.87 | $849K | Form 4 ↗ |
| Sep 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +11,797 | — | — | Form 4 ↗ |
| Sep 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −5,704 | $148.87 | $849K | Form 4 ↗ |
| Sep 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Option exercise | +5,637 | $30.96 | $107K | Form 4 ↗ |
| Sep 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Sold on the market10b5-1 plan | −3,471 | $139.95 | $486K | Form 4 ↗ |
| Sep 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −1,048 | $140.34 | $147K | Form 4 ↗ |
| Sep 1, 2026 | Mock James MCFO | Units vested | +2,475 | — | — | Form 4 ↗ |
| Sep 1, 2026 | Mock James MCFO | Tax withholding | −1,197 | $140.34 | $168K | Form 4 ↗ |
| Sep 1, 2026 | Hoge StephenPresident | Units vested | +9,283 | — | — | Form 4 ↗ |
| Sep 1, 2026 | Hoge StephenPresident | Tax withholding | −4,489 | $140.34 | $630K | Form 4 ↗ |
| Aug 28, 2026 | Hoge StephenPresident | Units vested | +611 | — | — | Form 4 ↗ |
| Aug 28, 2026 | Hoge StephenPresident | Tax withholding | −296 | $142.77 | $42.3K | Form 4 ↗ |
| Aug 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +329 | — | — | Form 4 ↗ |
| Aug 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −160 | $142.77 | $22.8K | Form 4 ↗ |
| Aug 28, 2026 | Mock James MCFO | Units vested | +329 | — | — | Form 4 ↗ |
| Aug 28, 2026 | Mock James MCFO | Tax withholding | −160 | $142.77 | $22.8K | Form 4 ↗ |
| Aug 27, 2026 | Hoge StephenPresident | Units vested | +1,437 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Hoge StephenPresident | Tax withholding | −695 | $149.66 | $104K | Form 4 ↗ |
| Aug 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +774 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −375 | $149.66 | $56.1K | Form 4 ↗ |
| Aug 27, 2026 | Mock James MCFO | Units vested | +774 | — | — | Form 4 ↗ |
| Aug 27, 2026 | Mock James MCFO | Tax withholding | −375 | $149.66 | $56.1K | Form 4 ↗ |
| Aug 6, 2026 | Bancel StephaneCEO, Director | Option exercise | +252,469 | $19.15 | $4.8M | Form 4 ↗ |
| Aug 5, 2026 | Bancel StephaneCEO, Director | Option exercise | +499,246 | $19.15 | $9.6M | Form 4 ↗ |
| Aug 5, 2026 | Bancel StephaneCEO, Director | Sold on the market10b5-1 plan | −499,246 | $57.52average | $28.7M | Form 4 ↗ |
| Jul 15, 2026 | Hoge StephenPresident | Option exercise | +53,336 | $19.15 | $1.0M | Form 4 ↗ |
| Jul 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −53,336 | $67.60 | $3.6M | Form 4 ↗ |
| Jul 8, 2026 | McDonnell Michael R.Director | AwardStock Option (Right to Buy) | +7,415 | — | — | Form 4 ↗ |
| Jul 8, 2026 | McDonnell Michael R.Director | AwardRestricted Stock Units | +7,351 | — | — | Form 4 ↗ |
| Jul 5, 2026 | Banque Soria EsterChief Commercial Officer | AwardStock Option (Right to Buy) | +18,658 | — | — | Form 4 ↗ |
| Jul 5, 2026 | Banque Soria EsterChief Commercial Officer | AwardRestricted Stock Units | +38,364 | — | — | Form 4 ↗ |
| Jul 2, 2026 | Mock James MCFO | Units vested | +1,452 | — | — | Form 4 ↗ |
| Jul 2, 2026 | Mock James MCFO | Tax withholding | −703 | $72.50 | $51K | Form 4 ↗ |
| Jun 15, 2026 | Hoge StephenPresident | Option exercise | +53,336 | $19.15 | $1.0M | Form 4 ↗ |
| Jun 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −53,336 | $51.37 | $2.7M | Form 4 ↗ |
| Jun 5, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +11,798 | — | — | Form 4 ↗ |
| Jun 5, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −5,705 | $51.59 | $294K | Form 4 ↗ |
| Jun 5, 2026 | Mock James MCFO | Units vested | +11,798 | — | — | Form 4 ↗ |
| Jun 5, 2026 | Mock James MCFO | Tax withholding | −5,705 | $51.59 | $294K | Form 4 ↗ |
| Jun 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Option exercise | +3,471 | $30.96 | $107K | Form 4 ↗ |
| Jun 4, 2026 | Klinger Shannon ThymeChief Legal Officer | Sold on the market10b5-1 plan | −3,471 | $50.00 | $174K | Form 4 ↗ |
| Jun 1, 2026 | Mock James MCFO | Units vested | +2,475 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Mock James MCFO | Tax withholding | −1,197 | $47.19 | $56.5K | Form 4 ↗ |
| Jun 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +2,165 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −1,047 | $47.19 | $49.4K | Form 4 ↗ |
| Jun 1, 2026 | Hoge StephenPresident | Units vested | +9,282 | — | — | Form 4 ↗ |
| Jun 1, 2026 | Hoge StephenPresident | Tax withholding | −4,488 | $47.19 | $212K | Form 4 ↗ |
| May 28, 2026 | Mock James MCFO | Units vested | +328 | — | — | Form 4 ↗ |
| May 28, 2026 | Mock James MCFO | Tax withholding | −159 | $47.61 | $7.6K | Form 4 ↗ |
| May 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +328 | — | — | Form 4 ↗ |
| May 28, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −159 | $47.61 | $7.6K | Form 4 ↗ |
| May 28, 2026 | Hoge StephenPresident | Units vested | +610 | — | — | Form 4 ↗ |
| May 28, 2026 | Hoge StephenPresident | Tax withholding | −295 | $47.61 | $14K | Form 4 ↗ |
| May 27, 2026 | Mock James MCFO | Units vested | +773 | — | — | Form 4 ↗ |
| May 27, 2026 | Mock James MCFO | Tax withholding | −374 | $47.03 | $17.6K | Form 4 ↗ |
| May 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Units vested | +773 | — | — | Form 4 ↗ |
| May 27, 2026 | Klinger Shannon ThymeChief Legal Officer | Tax withholding | −374 | $47.03 | $17.6K | Form 4 ↗ |
| May 27, 2026 | Hoge StephenPresident | Units vested | +1,437 | — | — | Form 4 ↗ |
| May 27, 2026 | Hoge StephenPresident | Tax withholding | −695 | $47.03 | $32.7K | Form 4 ↗ |
| May 21, 2026 | Afeyan NoubarDirector | Option exercise | +9,263 | $19.15 | $177K | Form 4 ↗ |
| May 21, 2026 | Afeyan NoubarDirector | Sold on the market | −9,263 | $46.84 | $434K | Form 4 ↗ |
| May 15, 2026 | Hoge StephenPresident | Option exercise | +53,336 | $19.15 | $1.0M | Form 4 ↗ |
| May 15, 2026 | Hoge StephenPresident | Sold on the market10b5-1 plan | −53,336 | $48.40 | $2.6M | Form 4 ↗ |
| May 6, 2026 | Rubenstein David M.Director | AwardStock Option (Right to Buy) | +9,681 | — | — | Form 4 ↗ |
| May 6, 2026 | Rubenstein David M.Director | AwardRestricted Stock Units | +2,092 | — | — | Form 4 ↗ |
| May 6, 2026 | Hussain AbbasDirector | AwardRestricted Stock Units | +8,371 | — | — | Form 4 ↗ |
| May 6, 2026 | Horning SandraDirector | AwardStock Option (Right to Buy) | +9,681 | — | — | Form 4 ↗ |
| May 6, 2026 | Horning SandraDirector | AwardRestricted Stock Units | +2,092 | — | — | Form 4 ↗ |
| May 6, 2026 | Nabel Elizabeth GDirector | AwardRestricted Stock Units | +8,371 | — | — | Form 4 ↗ |
| May 6, 2026 | Nader FrancoisDirector | AwardStock Option (Right to Buy) | +6,454 | — | — | Form 4 ↗ |
| May 6, 2026 | Nader FrancoisDirector | AwardRestricted Stock Units | +4,185 | — | — | Form 4 ↗ |
| May 6, 2026 | Tallett Elizabeth EDirector | AwardRestricted Stock Units | +8,371 | — | — | Form 4 ↗ |
| May 6, 2026 | Afeyan NoubarDirector | AwardStock Option (Right to Buy) | +12,908 | — | — | Form 4 ↗ |
| May 1, 2026 | Hussain AbbasDirector | Sold on the market10b5-1 plan | −5,682 | $46.63 | $265K | Form 4 ↗ |
| Apr 30, 2026 | Horning SandraDirector | Units vested | +16,233 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Rubenstein David M.Director | Units vested | +8,116 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Hussain AbbasDirector | Units vested | +16,233 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Nabel Elizabeth GDirector | Units vested | +16,233 | — | — | Form 4 ↗ |
| Apr 30, 2026 | Nader FrancoisDirector | Units vested | +12,174 | — | — | Form 4 ↗ |
SEC Form 4, public domain. The latest 40 of 64 Form 4 filings from the last 12 months are counted. A sale filled at several prices is one line at its average price. All Form 4s on EDGAR
Jobs, Midterm Elections, Apple, Palantir, McDonald’s, Moderna, and More to Watch This WeekBarrons.com, 4h ago
Merck stock rises as its cancer strategy gets personalTheStreet, 6h ago
How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataSimply Wall St., Oct 31
Prediction markets herald insider trading risks for private biotechsPharmaceutical Technology, Oct 30
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineZacks, Oct 30
Merck & Co., Inc. Q3 Earnings Call HighlightsMarketBeat, Oct 30
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Oct. 28GuruFocus.com, Oct 30
Invesco S&P 500 Equal Weight (RSP) Adds Moderna and PTC on Oct. 28GuruFocus.com, Oct 30Headlines are the outlets' views, not ours. Read the date before the headline. More on Yahoo Finance